Argenx Se (ARGX) Cash & Current Investments (2015 - 2026)
Argenx Se's (ARGX) quarterly Cash & Current Investments came in at $5.2 billion in Q2 2026, up 60.0% on a YoY basis from $3.2 billion in Q2 2025, and up 16.76% quarter-over-quarter from $4.4 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Cash & Current Investments (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Cash & Current Investments for 12 consecutive years, with $5.2 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash & Current Investments rose 60.0% year-over-year to $5.2 billion; the trailing twelve-month figure through Jun 2026 stood at $5.2 billion (up 60.0% YoY), and the FY2025 full-year result was $4.4 billion, down 99.76% from the prior year.
- Cash & Current Investments rose to $5.2 billion in Q2 2026 per ARGX's latest filing, from $4.4 billion in the prior quarter.
- Across five years, Cash & Current Investments topped out at $1880.4 billion in Q4 2024 and bottomed at -$1107.0 billion in Q2 2024.
- Historically, Cash & Current Investments has averaged $243.0 billion across 5 years, with a median of $3.2 billion in 2025.
- The widest YoY moves for Cash & Current Investments: up 59034.66% in 2024, down 55532.62% in 2024.
- Over 5 years, Cash & Current Investments stood at $1392.6 billion in 2022, then slumped by 99.77% to $3.2 billion in 2023, then surged by 59034.66% to $1880.4 billion in 2024, then tumbled by 99.76% to $4.4 billion in 2025, then gained by 16.76% to $5.2 billion in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $5.2 billion, $4.4 billion, and $3.2 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 7.85 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 7.99 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 5.18 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.14 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.16 Bn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 13.65 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.18 Bn |
| Dec 31, 2025 | 4.44 Bn |
| Jun 30, 2025 | 3.24 Bn |
| Dec 31, 2024 | 1,880.39 Bn |
| Jun 30, 2024 | -1,106.97 Bn |
| Dec 31, 2023 | 3.18 Bn |
| Jun 30, 2023 | 2.00 Bn |
| Dec 31, 2022 | 1,392.61 Bn |
| Jun 30, 2022 | 2.60 Bn |
| Dec 31, 2021 | 1,003.39 Bn |
| Jun 30, 2021 | 2.73 Bn |
| Mar 31, 2021 | 11.15 Mn |
| Dec 31, 2020 | 758.71 Bn |
| Sep 30, 2020 | 1.26 Mn |
| Jun 30, 2020 | 2.13 Bn |
| Dec 31, 2019 | 1.48 Bn |
| Jun 30, 2019 | 1.06 Bn |
| Dec 31, 2018 | 644.40 Mn |
| Jun 30, 2018 | 404.40 Mn |
| Dec 31, 2017 | 423.61 Mn |